Total results1,200
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AT8A2 | Q9NTI2 | Phospholipid-transporting ATPase IB (EC 7.6.2.1) (ATPase class I type 8A member 2) (ML-1) (P4-ATPase flippase complex alpha subunit ATP8A2) | Disease related genesEnzymesHuman disease related genes | 10 | Intellectual disability | Fusion and delivery mediation | 1 | 0.40 | ||
| AT8B1 | O43520 | Phospholipid-transporting ATPase IC (EC 7.6.2.1) (ATPase class I type 8B member 1) (Familial intrahepatic cholestasis type 1) (P4-ATPase flippase complex alpha subunit ATP8B1) | Disease related genesEnzymesHuman disease related genes | 10 | Intrahepatic cholestasis | Clinical-translation mediationFusion and delivery mediation | 1 | 0.40 | ||
| ATRN | O75882 | Attractin (DPPT-L) (Mahogany homolog) | Plasma proteinsPredicted membrane proteinsPredicted secreted proteins | 1 | Other mediation | 1 | 0.40 | |||
| AVR2B | Q13705 | Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB) | Cancer-related genesDisease related genesEnzymes | 1 | HeterotaxyNervous system paraneoplastic/autoimmune disorder | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.40 | ||
| B3GT2 | O43825 | Beta-1,3-galactosyltransferase 2 (Beta-1,3-GalTase 2) (Beta3Gal-T2) (Beta3GalT2) (EC 2.4.1.86) (UDP-galactose:2-acetamido-2-deoxy-D-glucose 3beta-galactosyltransferase 2) | 1 | Metabolism mediation | 1 | 0.40 | ||||
| BMPR2 | Q13873 | Bone morphogenetic protein receptor type-2 (BMP type-2 receptor) (BMPR-2) (EC 2.7.11.30) (Bone morphogenetic protein receptor type II) (BMP type II receptor) (BMPR-II) | Disease related genesEnzymesFDA approved drug targets | 1 | Joint derangementProstate cancerUrinary system disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.40 | ||
| BOC | Q9BWV1 | Brother of CDO (Protein BOC) | Predicted intracellular proteinsPredicted membrane proteins | 1 | Receptor-signaling mediation | 1 | 0.40 | |||
| BT2A1 | Q7KYR7 | Butyrophilin subfamily 2 member A1 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Fusion and delivery mediationImmune mediation | 1 | 0.40 | |||
| BT3A3 | O00478 | Butyrophilin subfamily 3 member A3 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Fusion and delivery mediationImmune mediation | 1 | 0.40 | |||
| BTLA | Q7Z6A9 | B- and T-lymphocyte attenuator (B- and T-lymphocyte-associated protein) (CD antigen CD272) | CD markersPredicted membrane proteinsPredicted secreted proteins | 1 | Lupus erythematosusSjogren syndromeSolid tumour/cancer | Clinical-translation mediationImmune mediation | 1 | 0.40 |